Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
1559- Api,    Dually Active Apigenin-Loaded Nanostructured Lipid Carriers for Cancer Treatment
- in-vitro, Lung, A549 - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Dose↓, selectivity↑,
1560- Api,    Apigenin as an anticancer agent
- Review, NA, NA
Apoptosis↑, Casp3∅, Casp8∅, TNF-α∅, Cyt‑c↑, MMP2↓, MMP9↓, Snail↓, Slug↓, NF-kB↓, p50↓, PI3K↓, Akt↓, p‑Akt↓,
1564- Api,    Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation
- in-vitro, Pca, 22Rv1 - in-vivo, NA, NA
MDM2↓, NF-kB↓, p65↓, P21↑, ROS↑, GSH↓, MMP↓, Cyt‑c↑, Apoptosis↑, P53↑, eff↓, Bcl-xL↓, Bcl-2↓, BAX↑, Casp↑, TumCG↓, TumVol↓, TumW↓,
1563- Api,  MET,    Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells
- in-vitro, Nor, HDFa - in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP - in-vivo, NA, NA
selectivity↑, selectivity↑, selectivity↓, ROS↑, eff↑, tumCV↓, MMP↓, Dose∅, eff↓, DNAdam↑, Apoptosis↑, TumAuto↑, Necroptosis↑, p‑P53↑, BIM↑, BAX↑, p‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Bcl-2↓, AIF↑, p62↑, LC3B↑, MLKL↑, p‑MLKL↓, RIP3↑, p‑RIP3↑, TumCG↑, TumW↓,
1562- Api,    Apigenin protects human melanocytes against oxidative damage by activation of the Nrf2 pathway
- in-vitro, Vit, NA
*SOD↑, *Catalase↑, *GPx↑, *MDA↓, *NRF2↑, *toxicity∅,
1561- Api,    Apigenin Reactivates Nrf2 Anti-oxidative Stress Signaling in Mouse Skin Epidermal JB6 P + Cells Through Epigenetics Modifications
- in-vivo, Nor, JB6
*NRF2↑, *DNMT1↓, *DNMT3A↓, *HDAC↓, *AntiCan↑,
1558- Api,    Preparation, characterization and antitumor activity evaluation of apigenin nanoparticles by the liquid antisolvent precipitation technique
- in-vitro, Liver, HepG2
BioAv↑, *toxicity∅, eff↑,
2631- Api,    Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells
- in-vivo, GC, NA - in-vitro, GC, AGS
ER Stress↑, Hif1a↓, EZH2↓, HDAC↓, TumAuto↑, p‑mTOR↓, AMPKα↑, GRP78/BiP↑, ROS↑, MMP↓, Ca+2↑, ATF4↑, CHOP↑,
2632- Api,    Apigenin inhibits migration and induces apoptosis of human endometrial carcinoma Ishikawa cells via PI3K-AKT-GSK-3β pathway and endoplasmic reticulum stress
- in-vitro, EC, NA
TumCP↓, TumCCA↑, Apoptosis↑, Bcl-2↓, BAX↑, Bak↑, Casp↑, ER Stress↑, Ca+2↑, ATF4↑, CHOP↑, ROS↑, MMP↓, TumCMig↓, TumCI↓, eff↑, P53↑, P21↑, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-xL↓,
2633- Api,    Apigenin induces ROS-dependent apoptosis and ER stress in human endometriosis cells
- in-vitro, EC, NA
TumCP↓, TumCCA↑, MMP↓, Ca+2↑, BAX↑, Cyt‑c↑, ROS↑, lipid-P↑, ER Stress↑, UPR↑, p‑ERK↓, ERK↓, JNK↑,
2634- Api,    Apigenin induces both intrinsic and extrinsic pathways of apoptosis in human colon carcinoma HCT-116 cells
- in-vitro, CRC, HCT116
TumCG↓, TumCCA↑, MMP↓, ROS↑, Ca+2↑, ER Stress↑, mtDam↑, CHOP↑, DR5↑, cl‑BID↑, BAX↑, Cyt‑c↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, Apoptosis↑,
2635- Api,  CUR,    Synergistic Effect of Apigenin and Curcumin on Apoptosis, Paraptosis and Autophagy-related Cell Death in HeLa Cells
- in-vitro, Cerv, HeLa
TumCD↑, eff↑, TumAuto↑, ER Stress↑, Paraptosis↑, GRP78/BiP↓, Dose↝,
2636- Api,    Apigenin unveiled: an encyclopedic review of its preclinical and clinical insights
- Review, NA, NA
*AntiCan↑, *cardioP↑, *neuroP↑, *Inflam↓, *antiOx↑, *hepatoP↑, ChemoSen↑,
2637- Api,    Apigenin Alleviates Endoplasmic Reticulum Stress-Mediated Apoptosis in INS-1 β-Cells
- in-vitro, Diabetic, NA
*other↝, *Insulin↑, ER Stress↓, *CHOP↓, *cl‑Casp3↓, *ROS↓, *Inflam↓, *TXNIP↓,
2638- Api,    Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death
- in-vitro, lymphoma, PEL
TumCD↑, TumAuto↑, ROS↓, P53↑, Catalase↑, STAT3↓,
2639- Api,    Plant flavone apigenin: An emerging anticancer agent
- Review, Var, NA
*antiOx↑, *Inflam↓, AntiCan↑, ChemoSen↑, BioEnh↑, chemoPv↑, IL6↓, STAT3↓, NF-kB↓, IL8↓, eff↝, Akt↓, PI3K↓, HER2/EBBR2↓, cycD1/CCND1↓, CycD3↓, p27↑, FOXO3↑, STAT3↓, MMP2↓, MMP9↓, VEGF↓, Twist↓, MMP↓, ROS↑, NADPH↑, NRF2↓, SOD↓, COX2↓, p38↑, Telomerase↓, HDAC↓, HDAC1↓, HDAC3↓, Hif1a↓, angioG↓, uPA↓, Ca+2↑, Bax:Bcl2↑, Cyt‑c↑, Casp9↑, Casp12↑, Casp3↑, cl‑PARP↑, E-cadherin↑, β-catenin/ZEB1↓, cMyc↓, CDK4↓, CDK2↓, CDK6↓, IGF-1↓, CK2↓, CSCs↓, FAK↓, Gli↓, GLUT1↓,
2640- Api,    Apigenin: A Promising Molecule for Cancer Prevention
- Review, Var, NA
chemoPv↑, ITGB4↓, TumCI↓, TumMeta↓, Akt↓, ERK↓, p‑JNK↓, *Inflam↓, *PKCδ↓, *MAPK↓, EGFR↓, CK2↓, TumCCA↑, CDK1↓, P53↓, P21↑, Bax:Bcl2↑, Cyt‑c↑, APAF1↑, Casp↑, cl‑PARP↑, VEGF↓, Hif1a↓, IGF-1↓, IGFBP3↑, E-cadherin↑, β-catenin/ZEB1↓, HSPs↓, Telomerase↓, FASN↓, MMPs↓, HER2/EBBR2↓, CK2↓, eff↑, AntiAg↑, eff↑, FAK↓, ROS↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, cl‑IAP2↑, AR↓, PSA↓, p‑pRB↓, p‑GSK‐3β↓, CDK4↓, ChemoSen↑, Ca+2↑, cal2↑,
2641- Api,    Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells
- in-vitro, BC, MDA-MB-231
TumCMig↓, TumCI↓, ITGB4↓,
2593- Api,    Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo
- in-vivo, BC, 4T1
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↑, ROS↑, p‑PI3K↓, PI3K↓, Akt↓, NRF2↓, AntiTum↑, OS↑,
2664- Api,    Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents
- Review, Var, NA
HDAC↓,
2594- Api,  docx,    Targeted hyaluronic acid-based lipid nanoparticle for apigenin delivery to induce Nrf2-dependent apoptosis in lung cancer cells
- in-vitro, Lung, A549
NRF2↓, ChemoSen↑,
2596- Api,  LT,    Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment
- Review, Var, NA
NRF2↓, chemoPv↑, ChemoSen↑,
2583- Api,  Rad,    The influence of apigenin on cellular responses to radiation: From protection to sensitization
- Review, Var, NA
radioP↑, RadioS↑, *COX2↓, *ROS↓, VEGF↓, MMP2↓, STAT3↓, AMPK↑, Apoptosis↑, MMP9↓, glucose↓,
2584- Api,  Chemo,    The versatility of apigenin: Especially as a chemopreventive agent for cancer
- Review, Var, NA
ChemoSen↑, RadioS↑, eff↝, DR5↑, selectivity↑, angioG↓, selectivity↑, chemoP↑, MAPK↓, PI3K↓, Akt↓, mTOR↓, Wnt↓, β-catenin/ZEB1↓, GLUT1↓, radioP↑, BioAv↓, chemoPv↑,
2585- Api,    Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1
- in-vitro, ACC, NA
GLUT1↓, TumCG↓,
2586- Api,  doxoR,    Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway
- in-vitro, HCC, Bel-7402
NRF2↓, ChemoSen↑,
2319- Api,    Apigenin sensitizes radiotherapy of mouse subcutaneous glioma through attenuations of cell stemness and DNA damage repair by inhibiting NF-κB/HIF-1α-mediated glycolysis
- in-vitro, GBM, NA
Glycolysis↓, NF-kB↓, p65↓, Hif1a↓, GLUT1↓, GLUT3↓, PKM2↓, RadioS↑, TumVol↓, TumW↓,
2318- Api,    Apigenin as a multifaceted antifibrotic agent: Therapeutic potential across organ systems
- Review, Nor, NA
*ROS↓, *PKM2↓, *Hif1a↓, *TGF-β↓, *AMPK↑, *Inflam↓, *PI3K↓, *Akt↑, *NRF2↑, *NF-kB↓,
2317- Api,    Apigenin intervenes in liver fibrosis by regulating PKM2-HIF-1α mediated oxidative stress
- in-vivo, Nor, NA
*hepatoP↑, *PKM2↓, *Hif1a↓, *MDA↓, *Catalase↓, *GSH↑, *SOD↑, *GPx↑, *TAC↑, *α-SMA↓, *Vim↓, *ROS↓,
2299- Api,    Flavonoids Targeting HIF-1: Implications on Cancer Metabolism
- Review, Var, NA
TumCP↓, angioG↓, Hif1a↓, VEGF↓, GLUT1↓, PKM2↓, Glycolysis↓,
2316- Api,    The interaction between apigenin and PKM2 restrains progression of colorectal cancer
- in-vitro, CRC, LS174T - in-vitro, CRC, HCT8 - in-vivo, CRC, NA
TumCP↓, PKM2↓, Glycolysis↓, TumCG↑, selectivity↑,
2314- Api,    Apigenin Restrains Colon Cancer Cell Proliferation via Targeted Blocking of Pyruvate Kinase M2-Dependent Glycolysis
- in-vitro, Colon, HCT116 - in-vitro, Colon, HT29 - in-vitro, Colon, DLD1
Glycolysis↓, PKM2:PKM1↓, β-catenin/ZEB1↓, cMyc↓,
1095- Api,    Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway
- Analysis, Colon, NA
Snail↓, EMT↓, NF-kB↓,
1077- Api,    Apigenin inhibits COX-2, PGE2, and EP1 and also initiates terminal differentiation in the epidermis of tumor bearing mice
- in-vivo, NMSC, NA
*COX2↓, COX2∅,
1008- Api,    Apigenin-induced lysosomal degradation of β-catenin in Wnt/β-catenin signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW480
Wnt/(β-catenin)↓, β-catenin/ZEB1↓, TumAuto↑, Akt↓, mTOR↓, tumCV↓, TumCCA↑, TumAuto↑, p‑Akt↓, p‑p70S6↓, p‑4E-BP1↓,
1024- Api,  CUR,    Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
- vitro+vivo, Melanoma, A375 - in-vitro, Melanoma, A2058 - in-vitro, Melanoma, RPMI-7951
TumCG↓, Apoptosis↑, PD-L1↓, STAT1↓, tumCV↓, T-Cell↑,
581- Api,  Cisplatin,    The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy
- in-vitro, Pca, CD44+
Bcl-2↓, survivin↓, Casp8↑, P53↑, Sharpin↓, APAF1↑, p‑Akt↓, NF-kB↓, P21↑, Cyc↓, CDK2↓, CDK4/6↓, Snail↓, ChemoSen↑,
577- Api,  PacT,    Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells
- in-vitro, Ovarian, SKOV3
p‑Akt↓, Bcl-xL↓, Bcl-2↓, AXL↓, Tyro3↓,
578- Api,  Cisplatin,    Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis
- in-vitro, Lung, A549 - in-vitro, BC, MCF-7 - in-vitro, CRC, HCT116 - in-vitro, Pca, HeLa - in-vitro, Lung, H1299
p‑P53↑,
583- Api,  Cisplatin,    Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study
- in-vitro, Laryn, HEp2
PI3K/Akt↓, GLUT1↓, Akt↓,
584- Api,  Cisplatin,    Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms
- in-vivo, Var, NA
Beclin-1↑, Casp3↑, Casp9↑, JNK↑, Mcl-1↓, Ki-67↓,
586- Api,  5-FU,    5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma
- in-vivo, HCC, NA
ROS↑, MMP↓, Bcl-2↓, Casp3↑, PARP↑,
589- Api,  5-FU,    Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro
- in-vitro, PC, Bxpc-3
GSK‐3β↓, NF-kB↓,
591- Api,  doxoR,    Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines
- in-vitro, AML, Jurkat - in-vitro, AML, THP1
ATP↓, Casp3↑, γH2AX↑,
5- Api,    Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer
- in-vitro, Pca, NA
HH↓, Gli1↓,
958- Api,    Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1α expression in non-small cell lung carcinoma
- in-vitro, Lung, NCIH1299
Hif1a↓, VEGF↓, VEGFR2↓, PDGF↓, angioG↓,
938- Api,  doxoR,    Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells
- vitro+vivo, HCC, HepG2
LDHA↓, HK2↓,
983- Api,    Apigenin acts as a partial agonist action at estrogen receptors in vivo
- in-vivo, NA, NA
ERα/ESR1↑, ERβ/ESR2↑,
177- Api,    Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression
- in-vitro, BC, MDA-MB-231
Cyc↓, CycB/CCNB1↓, CDK1↓, P21↑, PCNA↝, HDAC↓, TumCP↓, TumCCA↑, ac‑H3↑, TumW↓, TumVol↓,
307- Api,    Flavonoids inhibit angiogenic cytokine production by human glioma cells
- in-vitro, GBM, GL-15
TGF-β↓,

Showing Research Papers: 651 to 700 of 5754
Prev Page 14 of 116 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5754

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↑, 1,   GSH↓, 1,   lipid-P↑, 1,   NRF2↓, 5,   ROS↓, 1,   ROS↑, 10,   SOD↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 1,   MMP↓, 8,   MMP↑, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 2,   FASN↓, 1,   glucose↓, 1,   Glycolysis↓, 4,   HK2↓, 1,   LDHA↓, 1,   NADPH↑, 1,   PI3K/Akt↓, 1,   PKM2↓, 3,   PKM2:PKM1↓, 1,  

Cell Death ⓘ

Akt↓, 7,   p‑Akt↓, 4,   APAF1↑, 2,   Apoptosis↑, 8,   Bak↑, 1,   BAX↑, 5,   Bax:Bcl2↑, 2,   Bcl-2↓, 7,   Bcl-xL↓, 3,   cl‑BID↑, 1,   BIM↑, 1,   Casp↑, 3,   Casp12↑, 1,   Casp3↑, 6,   Casp3∅, 1,   cl‑Casp3↑, 2,   cl‑Casp7↑, 1,   Casp8↑, 2,   Casp8∅, 1,   cl‑Casp8↑, 2,   Casp9↑, 4,   cl‑Casp9↑, 2,   CK2↓, 3,   Cyt‑c↑, 9,   DR5↑, 2,   cl‑IAP2↑, 1,   JNK↑, 2,   p‑JNK↓, 1,   MAPK↓, 1,   Mcl-1↓, 1,   MDM2↓, 1,   MLKL↑, 1,   p‑MLKL↓, 1,   Necroptosis↑, 1,   p27↑, 1,   p38↑, 1,   Paraptosis↑, 1,   survivin↓, 1,   Telomerase↓, 2,   TumCD↑, 2,  

Kinase & Signal Transduction ⓘ

AMPKα↑, 1,   HER2/EBBR2↓, 2,   p‑p70S6↓, 1,  

Transcription & Epigenetics ⓘ

EZH2↓, 1,   ac‑H3↑, 1,   p‑pRB↓, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

CHOP↑, 3,   ER Stress↓, 1,   ER Stress↑, 5,   GRP78/BiP↓, 1,   GRP78/BiP↑, 1,   HSPs↓, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3B↑, 1,   p62↑, 1,   TumAuto↑, 6,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   P53↓, 1,   P53↑, 4,   p‑P53↑, 2,   PARP↑, 1,   p‑PARP↑, 1,   cl‑PARP↑, 2,   PCNA↝, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK2↓, 2,   CDK4↓, 2,   Cyc↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   CycD3↓, 1,   P21↑, 5,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State ⓘ

p‑4E-BP1↓, 1,   CSCs↓, 1,   EMT↓, 1,   ERK↓, 2,   p‑ERK↓, 1,   FOXO3↑, 1,   Gli↓, 1,   Gli1↓, 1,   GSK‐3β↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 4,   HDAC1↓, 1,   HDAC3↓, 1,   HH↓, 1,   IGF-1↓, 2,   IGFBP3↑, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   PI3K↓, 4,   p‑PI3K↓, 1,   STAT1↓, 1,   STAT3↓, 4,   TumCG↓, 4,   TumCG↑, 2,   Wnt↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

AntiAg↑, 1,   AXL↓, 1,   Ca+2↑, 6,   cal2↑, 1,   CDK4/6↓, 1,   E-cadherin↑, 2,   FAK↓, 2,   ITGB4↓, 2,   Ki-67↓, 1,   MMP2↓, 3,   MMP9↓, 3,   MMPs↓, 1,   PDGF↓, 1,   RIP3↑, 1,   p‑RIP3↑, 1,   Sharpin↓, 1,   Slug↓, 1,   Snail↓, 3,   TGF-β↓, 1,   TumCI↓, 4,   TumCMig↓, 3,   TumCP↓, 6,   TumMeta↓, 1,   Twist↓, 1,   Tyro3↓, 1,   uPA↓, 1,   β-catenin/ZEB1↓, 5,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   ATF4↑, 2,   EGFR↓, 1,   Hif1a↓, 6,   VEGF↓, 5,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 6,   GLUT3↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   COX2∅, 1,   IL6↓, 1,   IL8↓, 1,   NF-kB↓, 7,   p50↓, 1,   p65↓, 2,   PD-L1↓, 1,   PSA↓, 1,   T-Cell↑, 1,   TNF-α∅, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   CDK6↓, 1,   ERα/ESR1↑, 1,   ERβ/ESR2↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,   BioEnh↑, 1,   ChemoSen↑, 8,   Dose↓, 1,   Dose↝, 1,   Dose∅, 1,   eff↓, 2,   eff↑, 6,   eff↝, 2,   RadioS↑, 3,   selectivity↓, 1,   selectivity↑, 6,  

Clinical Biomarkers ⓘ

AR↓, 1,   EGFR↓, 1,   ERα/ESR1↑, 1,   EZH2↓, 1,   HER2/EBBR2↓, 2,   IL6↓, 1,   Ki-67↓, 1,   PD-L1↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   chemoP↑, 1,   chemoPv↑, 4,   OS↑, 1,   radioP↑, 2,   TumVol↓, 3,   TumW↓, 4,  
Total Targets: 205

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↓, 1,   Catalase↑, 1,   GPx↑, 2,   GSH↑, 1,   MDA↓, 2,   NRF2↑, 3,   ROS↓, 4,   SOD↑, 2,   TAC↑, 1,  

Mitochondria & Bioenergetics ⓘ

Insulin↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   PKM2↓, 2,  

Cell Death ⓘ

Akt↑, 1,   cl‑Casp3↓, 1,   MAPK↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Protein Folding & ER Stress ⓘ

CHOP↓, 1,  

DNA Damage & Repair ⓘ

DNMT1↓, 1,   DNMT3A↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

HDAC↓, 1,   PI3K↓, 1,  

Migration ⓘ

PKCδ↓, 1,   TGF-β↓, 1,   TXNIP↓, 1,   Vim↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   Inflam↓, 5,   NF-kB↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   cardioP↑, 1,   hepatoP↑, 2,   neuroP↑, 1,   toxicity∅, 2,  
Total Targets: 36

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page